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The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has
caused a significant number of fatalities and worldwide disruption. To identify drugs to
repurpose to treat SARS-CoV-2 infections, we established a screen to measure the
dimerization of angiotensin-converting enzyme 2 (ACE2), the primary receptor for the virus.
This screen identified fenofibric acid, the active metabolite of fenofibrate. Fenofibric acid
also destabilized the receptor-binding domain (RBD) of the viral spike protein and inhibited
RBD binding to ACE2 in enzyme-linked immunosorbent assay (ELISA) and whole cell-
binding assays. Fenofibrate and fenofibric acid were tested by two independent
laboratories measuring infection of cultured Vero cells using two different SARS-CoV-2
isolates. In both settings at drug concentrations, which are clinically achievable, fenofibrate
and fenofibric acid reduced viral infection by up to 70%. Together with its extensive history
of clinical use and its relatively good safety profile, this study identifies fenofibrate as a
potential therapeutic agent requiring an urgent clinical evaluation to treat SARS-CoV-2
infection.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for a pandemic,
which has cost over 1.9 million lives worldwide so far (Dhama et al., 2020; World Health
Organization, 2020; Wu et al., 2020). The emergence of new virus variants with higher
transmissibility rates is seeing rapid increases in infection rates and deaths across the world.
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et al., 2021; Voysey et al., 2021). While the clinical data are very
promising, the vaccines are not recommended or suitable in all
patient groups, e.g., children, those with hyperimmune disorders,
and those using immunosuppressants (Meo et al., 2021), and with
the global spread of viral variants of concern, e.g., Alpha-B.1.1.7,
Beta-B.1.351, Gamma-P.1, and Delta-B.1.617.2, it is presently
unclear whether the current vaccines will offer sufficient
protection to emerging strains (Meo et al., 2021). While in a
few countries vaccination programs are progressing at speed,
vaccine uptake rates are variable and for most lowmiddle-income
countries, significant proportions of the population are unlikely
to be vaccinated until 2022. Furthermore, while vaccination has
been shown to reduce infection rates and severity of disease, we
are as yet unsure of the strength and duration of the response.
Therapies are still urgently needed to manage COVID-19 patients
who develop symptoms and/or require hospitalization.
The virus gains entry to human cells by the receptor-binding
domain (RBD) of the viral spike protein binding to angiotensin-
converting enzyme 2 (ACE2) on human cells (Clausen et al.,
2020; Hoffmann et al., 2020). Although other receptors of the
virus have been identified (Cantuti-Castelvetri et al., 2020; Daly
et al., 2020), drugs that block virus binding to ACE2 may
substantially reduce virus uptake, thereby reducing/relieving
symptoms in patients with an active infection or reduce
transmission of the virus to uninfected individuals.
While the rapid escalation of the SARS-CoV-2 epidemic leaves
insufficient time to develop new drugs via traditional pipelines,
drug repurposing offers an expedited and attractive alternative.
Drugs which are repurposed are available for immediate clinical
use and their pharmacokinetic and safety profiles are usually well
described. This has already proven true, with the identification
that dexamethasone reduces mortality of SARS-CoV-2 patients
(RECOVERY Collaborative Group et al., 2021) and remdesivir
decreases the time needed for patients to recover from infection
(Beigel et al., 2020). In these cases, although the drugs are
technically being repurposed, their use still depends on the
drug’s recognized mechanism of action. It is less obvious
which drugs might have a novel mechanism of action and
interfere with SARS-CoV-2 binding and cellular entry
mediated by ACE2. To this end, we recently developed an
assay to measure the viral spike protein’s RBD binding to
ACE2 (Lima et al., 2021).
Structural studies have shown that ACE2 is a dimer and that
there may be multiple spike RBDs interacting with each ACE2
dimer (Yan et al., 2020). Molecular dynamic simulations have
suggested considerable flexibility in ACE2 and this might allow
multiple ACE2 dimers to bind to each spike trimer (Barros et al.,
2021). If this were to be the case, the dimerization of ACE2 would
lead to multiple contacts with each spike trimer, increasing the
avidity of the binding. Alternatively, dimerization of ACE2 might
sterically hinder the protomers from binding to the spike protein.
It therefore seems reasonable that the extent of ACE2
dimerization might affect the avidity of RBD binding.
Furthermore, dimerization has been shown to affect the
internalization of other receptors. For example, dimerization
of EGF or FGF receptors promotes their endocytosis (Wang
et al., 2005; Opalinski et al., 2017) and different mechanisms of
internalization may exist for monomeric and dimeric GH
receptors (Gent et al., 2002). This led to the hypothesis that
drugs that altered dimerization of ACE2 might affect viral
infection by endocytosis. In order to test this hypothesis, we
developed an assay to measure dimerization of ACE2, making use
of the NanoBIT protein interaction system (Dixon et al., 2016).
This is based on a modified luciferase (NanoLuc) which has been
split into two catalytically incomplete components, LgBIT and
SmBIT, that must bind together to form an active luciferase.
LgBIT and SmBIT associate with low affinity but when fused to
other proteins that interact with each other, colocalization of the
fusion proteins allows an active luciferase to be formed (Dixon
et al., 2016). Here, we have used this system to measure
dimerization of ACE2 and screened a library of approved
drugs (FMC Library (Khanim et al., 2011)) using an
unsupervised approach to identify drug candidates for
repurposing. Our experiments demonstrated that fenofibric
acid (Supplementary Figure S1), the active metabolite of the
oral hyperlipidaemic drug fenofibrate, apparently induced ACE2
dimerization and destabilized the spike RBD inhibiting binding of
spike RBD to ACE2. Importantly and as hypothesized,
fenofibrate-induced changes in RBD-ACE2 interactions
correlated with significantly lower infection levels (< 60%) and
viral release in cell culture models using live SARS-CoV-2. Our
data combined with unpublished data from other groups and the
existing clinical knowledge of fenofibrate identify it as a strong
candidate for treating SARS-CoV-2 infections.
MATERIALS AND METHODS
Materials
The plasmid pcDNA3 encoding ACE2 was obtained from
GenScript (OHu20260); the plasmid encoding prolactin (PRL)
was obtained from Sino Biological (HG10275-CY). OptiMEM
and Lipofectamine 2000 were obtained from Thermo Fisher
Scientific. NanoBIT and high affinity binary interaction
technology (HiBIT) detection reagents, flexicloning transfer
systems (C8820 and C9320), and NanoBIT starter kit (N2015)
were obtained from Promega. This provides protein kinase A
regulatory (PRKAR2) and catalytic subunits (PRKACA) with
NanoBIT reporters which serve as a positive interaction control.
Anti-His antibody was from Thermo Fisher Scientific (37-2900)
and anti-FLAG from Cell Signaling Technology (#2368). The
plasmid pcDNA3 encoding ACE2-FLAG was obtained from
GenScript (OHu20260) and pcDNA3 encoding ACE2-SBP-
6xHis was obtained from Thermo Fisher Scientific. S1 protein
was obtained from the National Institute of Biological Standards
(United Kingdom).
Molecular Biology
Full-length ACE2 was amplified by PCR using primers (forward
GACCGCGATCGCCATGTCAAGCTCTTCCTGGCTCCT
TCT; reverse GATGGTTTAAACAAAGGAGGTCTGAACATC
ATCAGTG) to introduce a 5’ Sgf1 restriction site immediately
prior to the start codon and a Pme1 restriction site directly after
the codon encoding the last phenylalanine residue. The PCR
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product was digested with Flexiblend (Sgf1 and Pme1), gel
purified, and ligated into pF4ACMV before verifying by
sequencing. The insert was subsequently transferred into either
pFC34K (encoding LgBIT) or pFC36K (encoding SmBIT) using
the C-terminal flexicloning system to generate C-terminal fusion
proteins. The tagged ORFs are then expressed under the control
of a herpes simplex virus (HSV) thymidine kinase promoter. Atg5
and Atg16 tagged with NanoBIT reporters were generated by the
authors previously (Crowley et al., 2020).
NanoBIT and HiBIT Assays
HEK-293 cells were grown in DMEM supplemented with 10% (v/
v) fetal calf serum (FCS) and penicillin-streptomycin (50 U/ml).
For each well of 384 plates, 1.25 μL of OptiMEM containing
10 ng/μL of each of pFC34K ACE2 and pFC36K ACE2 was mixed
with an equal volume of OptiMEM containing 8% lipofectamine-
2000. After incubating at room temperature for 30 min, the
transfection mix was mixed with 10 volumes of well-dispersed
HEK-293 cells (300,000 cells/mL) in 10% FCS/DMEM without
antibiotics and 25 μL plated per well of white 384-well plates. The
two outer rows of the plate were filled with 25 μL media as a
humidity barrier. After 48 h, 2.8 μL drug at 10 x the final
concentration was added per well and incubated for 1 h.
Detection reagent was prepared by mixing per well 6.33 μL of
detection reagent buffer, 0.33 μL of the substrate, and 8.34 μL of
OptiMEM containing 10 mM Hepes prewarmed to 37°C. 15 μL
detection reagent was added per well and gently mixed and
luminescence was read every 10 min over 30 min.
To test whether the drugs inhibit NanoLuc directly, HiBIT-
RBD was prepared as described previously (Lima et al., 2021) and
the drug was added to the desired final concentration and mixed
with an equal volume of HiBIT detection reagent and
luminescence measured. The results were compared to the
luminescence measured using HiBIT-RBD containing DMSO.
Tomeasure whether the drugs inhibited the binding of HiBIT-
RBD to ACE2, drugs were tested in the binding assay as
previously described on ice (Lima et al., 2021). Alternatively,
binding was measured after 20 min at 37°C. For experiments in
which the order of addition was varied, either cell expressing
ACE2 or HiBIT-RBD cell culture supernatant was incubated at
37°C for 30 min prior to mixing and binding after a further
20 min measured as described above. To control any effects of the
drug on cell number, parallel plates were stained with
sulforhodamine B (Witham et al., 2007) and the luminiscence
measurements were normalized to this.
Precipitation of ACE2 Complexes
HEK-293 cells were transfected by mixing (for each well of a six-
well plate) 0.5 μg of each pcDNA3 ACE2-FLAG and pcDNA3
ACE2-SBP-6xHis in 50 μL OptiMEM. pCMV3 Prolactin (PRL)
was used as a negative control in the absence of plasmids
encoding ACE2. 50 μL of 8% Lipofectamine-2000 in
OptiMEM was added to plasmid DNA and after 30 min
incubation, 1 ml of HEK-293 cells (300,000 per ml) was
added, and the suspension was plated per well in six-well
plates. After 12 h incubation, the cell culture supernatant was
gently removed and replaced with fresh DMEM containing 10%
FCS. After a further 6 h, the medium was again removed and the
cells were lysed in 250 µL RIPA as previously described
(Richardson et al., 1997). Lysates were cleared by
centrifugation (20,000 g, 10 min, and 4°C), 30 μL saved for
analysis, while 200 μL was mixed with 20 µL of streptavidin
beads for 2 h at 4°C. The beads were washed twice with RIPA
and once with Tris-buffered saline before being separated on a
4–12% SDS-PAGE gel and transferred to PVDF and proteins
were detected with anti-FLAG (1/1,000) or anti-His (0.08 μg/ml)
antibodies.
Expression of the Spike S1-Receptor
Binding Domain for ELISA
Secreted Spike S1-RBD was produced stably using CHOZN GS−/
− cells in suspension employing a plasmid encoding residues
319–591 of 2019-nCoV S (upstream of a C-terminal HRV3C
protease cleavage site, mFc tag, and 8xHis Tag, gifted by Jason S.
McLellan, University of Texas, Austin), as described by Tree et al.
(2020). The coding region of RBD-Fc was subcloned into a
modified pCGS3 (Merck/formally known as Sigma-Aldrich)
for glutamine selection in CHOZN GS−/− cells. Briefly, a
RBD-Fc stable clone was obtained by electroporation with 2 ×
106 cells and 5 μg endotoxin-free plasmids using Amaxa kit V and
program U24 with Amaxa Nucleofector 2B (Lonza, Switzerland).
Electroporated cells were subsequently plated in 96 wells at 500
cells/well in Plating Medium containing 80% EX CELL® CHO
Cloning Medium (Cat.no C6366) and EX CELL CHO CD Fusion
serum-free media without glutamine. High-expressing clones
were scaled up in serum-free media without L-glutamine in
50 ml TPP TubeSpin® shaking Bioreactors (180 rpm, 37°C, and
5% CO2) for RBD-Fc production. A HiTrap Protein G, HP
column (GE Healthcare, US), equilibrated in 1x PBS prior to
use, was employed to purify the Spike S1-RBD, eluting with
glycine (100 mM, pH 2.7). Purity was confirmed using SDS-
PAGE with Coomassie stain and quantified using the
bicinchoninic acid assay (Thermo Scientific).
ELISA Measuring RBD-ACE2 Binding
An RBD-ACE2 interaction ELISA was performed as described by
Tree et al. (2020). Streptavidin (3 μg/ml; Fisher) was precoated
onto the surface of 96-well plates (high binding; Greiner) in
Na2CO3 buffer (50 mM; pH 9.6; 1 h; 37°C). Plates were washed 3x
(300 μL PBS containing 0.2% w/v Brij35) prior to blocking for 1 h
at 37°C with 50 μL PBS, 0.2% w/v Brij35, and 1% w/v casein. After
washing 3x with PBS, plates were coated with 50 μL of 100 ng/ml
biotin-ACE2 (Sino Biological) in PBS containing 0.2% w/v Brij35
and 1% w/v casein for 1 h at 37°C. Plates were then washed and
incubated at room temperature in 50 µL of 5 μg/ml RBD in PBS
containing 0.2% w/v Brij35 and 1% w/v casein for 30 min in the
presence or absence of test drugs. Plates were incubated (1 h;
37°C) to allow binding before three washes. Bound RBD was
detected by incubation (1 h; 37°C) with rabbit anti-SARS-CoV-2
spike RBD (Stratech) (1:2000 v/v) in PBS containing 0.2% w/v
Brij35 and 1% w/v casein. Following three further washes, plates
were incubated (30 min; at 37°C) with horseradish peroxidase-
conjugated donkey anti-rabbit IgG (1:2500 v/v), in PBS
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containing w/v Brij35 and 1% w/v casein. Plates were washed five
times before the addition of 3,3′,5,5′-tetramethylbenzidine
substrate, prepared as per manufacturer’s instructions (Sigma-
Aldrich). Color development was halted after 10 min by the
addition of H2SO4 (2 M) and quantified at λabs  450 nm
using a Tecan Infinite M200 Pro multiwell plate reader (Tecan
Group). Specific binding was determined by subtracting the
absorbance measured in samples lacking ACE2.
Differential Scanning Fluorimetry
Differential scanning fluorimetry (DSF) was conducted with
1 μg RBD in 40 μL PBS (pH 7.6) with 1.25x SYPRO™ Orange
(Invitrogen) and either H2O, sodium acetate, or fibrates in 96-
well qPCR plates (AB Biosystems). AB Biosystems, StepOne
Plus, and qPCR machine with a TAMRA filter were employed
to perform melt curve experiments, increasing the
temperature by + 0.5°C every 30 s, from 25 to 90°C. First-
order differential plots were calculated after smoothing
(Savitzky–Golay, nine neighbors, second-order polynomial)
using Prism 8 (GraphPad). The peak maxima of the first-order
differential plots were determined with MATLAB software
(R2018a, MathWorks) and used to calculate the change in Tm
in the presence of fibrates. Control wells without RBD, but
containing sodium acetate or fibrates, were tested to confirm
that altered Tm values were a result of protein-ligand
interactions and not a result of an interaction between the
drug and the dye.
Modified “CETSA” Assay
A modified version of the cellular thermal shift assay (Martinez
et al., 2018) was performed in which 200 μL HiBIT-RBD cell
culture supernatant (Lima et al., 2021) cleared of cells by
centrifugation (150 g, 3 min) was mixed with an equal volume
of 460 μM fenofibric acid for 20 min at 37°C for 20 min. 30 μL
samples were incubated for 7 min at a temperature ranging from
37 to 70°C, quenched on ice, and then centrifuged (20,000 g,
20 min, and 4°C). Soluble RBD in the supernatant was measured
by mixing 10 μL with 10 μL HiBIT detection reagent.
SARS-CoV-2 Infection Experiments
(hCOV-19/England/2/2020 Strain)
Experiments using live SARS-CoV-2 experiments were all
performed in approved BSL 3/CL3 facilities by staff trained to
work with BSL3/CL3 infectious organisms using standardized
safety and decontamination protocols. Vero cells (ATCC® CCL-
81) were washed with PBS, dislodged with 0.25% Trypsin-EDTA
(Sigma life sciences), and seeded into 96-well imaging plates
(Greiner) at a density of 8 × 103/well in culture media (DMEM
containing 10% FBS, 1% penicillin and streptomycin, 1%
L-glutamine, and 1% non-essential amino acids). The next day,
cells were infected with SARS-CoV-2 strain hCOV-19/England/
2/2020, isolated by Public Health England (PHE) from the first
patient cluster in the United Kingdom on January 29, 2020. Virus
stock 106 IU/ml (kind gift from Christine Bruce, PHE) was
diluted 1/150 in culture media allowing 25 μL per well. The
virus was then diluted further with 25 μL per well of media
containing the drugs being evaluated at twice the desired final
concentration to give 1x drug and a final virus dilution of 1/300.
Cells were then infected with the virus (167 IU/well) and cultured
for 24 or 48 h. After the infection period, supernatants were
harvested and frozen prior to analysis by qRT-PCR, and cells
were fixed in ice-cold methanol. Cells were then blocked in PBS
containing 10% FBS and stained with rabbit anti-SARS-CoV-2
spike protein, subunit 1 (The Native Antigen Company), followed
by Alexa Fluor 555-conjugated goat anti-rabbit IgG secondary
antibody (Invitrogen, Thermo Fisher Scientific). Cell nuclei were
stained with Hoechst 33,342 (Thermo Fisher Scientific). After
washing with PBS, cells were imaged and analyzed using a
Thermo Scientific CellInsight CX5 High-Content Screening
(HCS) platform. Infected cells were scored by perinuclear
fluorescence above a set threshold determined by positive
(untreated) and negative (uninfected) controls. A minimum of
nine fields and 5,000 nuclei per well in triplicate or quadruplicate
wells per treatment were scored in each experiment. All
experiments were performed 2–4 times.
SARS-CoV-2 Plaque Formation Assay (Italy/
UniSR1/2020 Strain)
Experiments using live SARS-CoV-2 experiments were all
performed in approved BSL 3/CL3 facilities by staff trained to
work with BSL3/CL3 infectious organisms using standardized
safety and decontamination protocols. Vero cells were plated at
2.5 × 105 cell/well in 24-well plates in Essential-Modified Eagle
Medium (EMEM, Lonza) supplemented with 10% FCS
(EuroClone) (complete medium). Twenty-four hours later,
cells were incubated with compounds in 250 μL of complete
medium 1 h prior to infection and then incubated with virus
suspension (pretreatment) containing 50 plaque-forming units
(PFU) of Italy/UniSR1/2020 strain (GISAID accession ID:
EPI_ISL_413489). After incubation for 1 h at 37°C,
supernatants were discarded, and 500 µL of 1% methylcellulose
(Sigma Chemical Corp) overlay dissolved in a complete medium
was added to each well. Alternatively, Vero cells were incubated
with compounds together with a virus suspension containing
50 PFU (cotreatment) in a total volume of 300 μL complete
medium for 1 h. Supernatants were discarded and the
methylcellulose overlay was added as described above. After 3
days, cells were fixed using 6% formaldehyde/PBS solution for
10 min and stained with 1% crystal violet (Sigma Chemical Corp)
in 70% methanol for 1 h. The plaques were counted under a
stereoscopic microscope (SMZ-1500, Nikon) and photographed
using the EVOS M5000 system (Thermo Fisher).
Quantitative Real-Time PCR for
SARS-CoV-2
Cell culture supernatant from infection experiments was heat-
inactivated at 56°C for 60 min following PHE protocols in the
NHS Turnkey Labs based in the University of Birmingham
Medical School. Viral RNA was reverse transcribed and
quantified in the culture supernatant using the 1-step SARS-
CoV-2 VIASURE Real-Time PCR Detection Kit (Prolab
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Diagnostics/CerTest Biotec) according to the manufacturer’s
instructions. Briefly, 15 μL of rehydrated Reaction-Mix was
combined with 5 μL of either heat-inactivated cell culture
supernatant, positive virus RNA control, or negative control
before cycling in an Agilent AriaMX Real-Time thermal cycler
using the following cycle conditions: reverse transcription at
45°C for 15 min and initial denaturation at 95°C for 2 min
followed by 45 cycles of 95°C for 10 s, 60°C for 50 s.
Fluorimetric data were collected during the extension step
for FAM (ORF1ab gene), ROX (N gene), Hex (internal
control), and cycle thresholds (Ct) calculated for each gene.
Relative expression was calculated by subtracting the virus
control Ct values from drug treatment samples and
transforming the data using 2−ΔCt.
Statistical Analysis
All pairwise comparisons were performed using paired t-tests or
Mann–Whitney U tests where normal distribution was not
assumed. Multiple comparisons were done using ANOVA.
RESULTS
Validation of ACE2 Dimerization Assay
To develop an assay to measure dimerization of ACE2, two
separate plasmids were created encoding ACE2 fused in frame
at its C terminus to one of the NanoBIT reporters, SmBIT or
LgBIT (Figure 1A). When these constructs were expressed in
HEK293 cells, luminescence was observed that was
FIGURE 1 | ACE2 dimerization assay. A. Schematic showing ACE2 tagged with LgBIT and SmBIT. B. HEK-293 cells were transfected with combinations of
plasmids encoding LgBIT or SmBIT fused to either protein kinase A regulatory subunit (PRKAR2) or catalytic subunit (PRKACA), ATG5 or ACE2. The results (mean ± SD,
n  5) were normalized to the luminescence measured in cells transfected with protein kinase A reporters (positive control). C. HEK-293 cells were transfected with
plasmids encoding ACE2 NanoBIT reporters under the control of the HSV TK promoter and ACE2 or prolactin (PRL) under the control of the CMV promoter. The
results (mean ± SD, n  4) were normalized to the luminescence measured in cells transfected with protein kinase A reporters and prolactin. D. HEK-293 cells were
transfected with NanoBIT-tagged ACE2 reporters and incubated with sodium valproate or clofibrate at a concentration equal to 1x, 2x, or 3x the reported Cmax of the
drug. After 1 h, luminescence was measured and normalized (mean ± SD, n  4) to that measured in cells treated with DMSO. E. A series of other fibrates were similarly
evaluated in the assay. The luminescence measured (mean ± SD, n  5–11) was significantly different to that measured in cells treated with solvent where shown (*p <
0.05; **p < 0.01; ***p < 0.005). When these fibrates were incubated with purified LgBIT and HiBIT-RBD to create a constitutively active NanoLuc, each of these fibrates
was found to inhibit nanoluciferase (bezafibrate 35 ± 7%, ciprofibrate 55 ± 6%, fenofibric acid 48 ± 7%, fenofibrate 69 ± 5%, and gemfibrozil 61 ± 2% of the activity
measured in the presence of DMSO). To correct this, the luminescence measurements from cells treated with fibrates in cells were divided by the fractional inhibition
noted above to estimate the effect of the drugs on dimerization. These corrected results are shown as a horizontal line with double-headed arrows. F. HEK293 cells
expressing either NanoBIT-tagged ACE2 or a combination of Atg5-SmBIT and Atg16-LgBIT were incubated with fenofibric acid (230 µM) and luminescence measured
(mean ± SD, n  4).
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approximately 20% of that generated by the protein kinase A
positive controls comprised of LgBIT and SmBIT fused to the
protein kinase A regulatory (PRKAR2) and catalytic (PRKACA)
subunits, respectively (Figure 1B). Cotransfection of plasmids
encoding ACE2 fused to either LgBIT or SmBIT and PRKAR2 or
PRKACA subunits fused to the complementary NanoBIT
reporter or co-transfection of NanoBIT-tagged ATG5 and
PRKAR2, two proteins not known to interact, did not generate
luminescence indicating that the assay measured ACE2
dimerization (Figure 1B). To further confirm the assay
measured ACE2 dimerization, cells were transfected with a
plasmid encoding untagged ACE2 as well as ACE2 tagged
with LgBIT or SmBIT. The untagged ACE2 was expressed
under the control of a CMV promoter, which provides
substantially higher level expression than the HSV TK
promoter which controls the expression of the NanoBIT-
tagged ACE2. If the assay measures dimerization, the
expression of the untagged ACE2 would be expected to
suppress the luminescence by competing with the tagged
ACE2 in dimers. To ensure that the effect observed did not
result from competition for transcription factors, rather than as a
result of the untagged ACE2 competing with NanoBIT-tagged
ACE2, an unrelated gene (prolactin-PRL) was also expressed
under the control of the CMV promoter. High-level CMV-driven
expression of untagged ACE2, but not untagged PRL, suppressed
the luminescence signal generated by ACE2-NanoBIT reporters
(Figure 1C). Likewise, untagged ACE2 or PRL did not suppress
the luminescence measured with the NanoBIT-tagged protein
kinase A subunits (Figure 1C), thus confirming the specificity of
the assay.
Identification of ACE2 Dimerization
Modulators
The ACE2-NanoBIT assay was used to screen a custom in-house
library of approximately 100 approved drugs at a final
concentration equal to their Cmax in patients (FMC1 Library)
(Khanim et al., 2011). Sodium valproate and clofibrate both
increased the dimerization signal by approximately 33 and
56%, respectively. To confirm this, fresh compounds were
purchased and retested at a concentration equal to their Cmax
in patients and multiples of this. Both compounds significantly
increased the measured luminescence, confirming the results of
the screen (Figure 1D). Although previously approved, clofibrate
has subsequently been withdrawn due to unacceptable toxicity
(Oliver, 2012). However, several other fibrates, bezafibrate,
ciprofibrate, fenofibrate, and gemfibrozil, are still in clinical
use. Apart from fenofibrate, these all bear a carboxylic acid,
whereas fenofibrate is an isopropyl ester prodrug of fenofibric
acid (Supplementary Figure S1). Noting that sodium valproate is
also a lipophilic carboxylic acid, fenofibric acid was tested in the
dimerization assay. All of the fibrates (tested at 230 μM, the Css of
clofibrate (Männistö et al., 1975)) modestly, but significantly,
increased luminescence (Figure 1E). However, they also
substantially decreased the luminescence generated by mixing
LgBIT with HiBIT-tagged RBD (which binds LgBIT with high
affinity and independently of other interacting molecules). This
suggested that the drugs inhibited NanoLuc directly and the
measured luminescence underestimated dimerization. When
the luminescence measured in the assay was corrected to take
into account inhibition of nanoluciferase (Figure 1E), fenofibric
acid emerged as the most effective, apparently increasing
dimerization by approximately twofold. In contrast to this,
fenofibrate did not increase dimerization. The increase in
luminescence was also time-dependent, reaching a maximum
after 30 min exposure to the drug (Supplementary Figure S2). To
provide evidence for the specificity of the interaction, the effect of
fenofibric acid on Atg5 and Atg16 tagged with LgBIT and SmBIT
(Crowley et al., 2020) was investigated. Unlike ACE2, fenofibric
acid did not increase the interaction of Atg5-Atg16 (Figure 1F).
To confirm these results, HEK-293 cells were transfected with
plasmids encoding ACE2 tagged with streptavidin binding
protein and a His-tag or ACE2 with a FLAG tag. Cells were
exposed to drug and lysed and ACE2 complexes were purified
using streptavidin beads. Following immunoblotting, ACE2-
FLAG was only detected in lysates from cells transfected with
both plasmids and not from cells transfected with one plasmid
alone, confirming that the assay measured the interaction of
ACE2. However, when cells were exposed to the fibrates, the
amount of ACE2-FLAG detected on the beads was not
substantially altered (Supplementary Figure S3).
Effect of Fibrates on S Protein RBD
To evaluate whether fibrates affect the viral spike protein RBD,
the thermal stability of RBD in the presence and absence of
fibrates was investigated using DSF. Changes in Tm of a protein in
the presence of a ligand are indicative of binding and have
previously been utilized to probe for protein-ligand
interactions (Niesen et al., 2007). All of the fibrates altered Tm
of RBD (46.4°C) although the greatest destabilization was
observed with bezafibrate and ciprofibrate (ΔTm  -1.9°C,
(Supplementary Figure S4). A smaller effect was observed
with fenofibric acid (ΔTm  −1.4°C) but this was detectable at
concentrations as low as 30 μM (Figures 2A,B). Although
fenofibrate also destabilized RBD, this was only observed at
higher drug concentrations (≥270 μM, Supplementary Figure
S4). Acetate, a carboxylic acid lacking the lipophilic moieties
found in the fibrates, had no significant effect on RBD Tm
(Figure 2D, Supplementary Figure S4D) indicating that the
lipophilic moieties are required. In addition, fenofibric acid also
decreased the stability of the S1 protein (Supplementary
Figure S4C).
To confirm these results, we used a modification of a cellular
thermal shift assay in which aggregates of thermally unfolded
protein are cleared by centrifugation. Consistent with the DSF
assay, in this assay, fenofibric acid decreased Tm of RBD by 2-3°C
(Figure 2C).
Fenofibric Acid Inhibits ACE2-RBD Binding
An ELISA consisting of immobilized, recombinant ACE2 was
employed to determine the inhibitory effect of fibrates on RBD-
ACE2 binding. All fibrates screened demonstrated significant
inhibition of binding at a concentration of 230 μM, the Cmax
of clofibrate (Figure 2D). The binding of RBD to ACE2 expressed
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in COS cells wasmeasured as previously described (Lima et al., 2021).
When these assays were conducted on ice to minimize endocytosis
and a membrane impermeant detection reagent was used to detect
extracellular binding, no inhibition of RBDbinding was observedwith
any of the fibrates (Supplementary Figure S5A) and in some cases,
there was apparently a modest stimulation. The assay was adapted for
use at 37°C and reached a steady state by 20min (data shown). Using
this revised protocol, fenofibric acid was found to modestly, but
significantly, inhibit RBD binding to ACE2 (Figure 2E). This was
not due to toxicity as 99 ± 1% (n  4) of the cells excluded trypan blue
after similar exposure to drug. Furthermore, when either RBD or cells
expressing ACE2 were preincubated with fenofibric acid, significantly
more inhibition of the binding was observed than when all three were
coincubated, consistent with the drug affecting both RBD and ACE2
(Figure 2F). Lastly, in a preliminary experiment, fenofibric acid
inhibited binding to fixed Vero cells (Supplementary Figure S5).
These data indicate that fenofibrate/fenofibric acid interferes with
spike RBD binding to ACE2.
Fenofibrate Inhibits Infection of Vero Cells
by the hCOV-19/England/2/2020 Virus
Isolate
To evaluate the potential therapeutic effect of fenofibrate/fenofibric
acid on SARS-CoV-2 virus, infection experiments were performed
independently in two separate laboratories. Using the hCOV-19/
England/2/2020 virus strain, Vero cells were coincubated with virus
and fibrates before fixing and staining for spike protein and
counterstaining nuclei with Hoechst. Analysis after 24 h
incubation of Vero cells with SARS-CoV-2 virus identifies
changes in primary infection rates, whereas by 48 h, virus particles
released by infected Vero cells into the culture medium infect other
FIGURE 2 | Effect of fenofibrate on RBD and RBD binding to ACE2 A. Differential scanning fluorimetry (DSF). Tm of 1 μg RBD alone or with increasing
concentrations of fenofibric acid. The results (mean ± SD, n  3) were significantly different from RBD where shown (***p < 0.001; **p < 0.01; *p < 0.05; paired t-test). B.
The first differential of the thermal stability of 1 μg RBD alone (solid line) or with 2.5 mM fenofibric acid (dotted line). A direct interaction of fenofibric acid with SYPRO™
Orange dye (in the absence of RBD) was not observed.C.Cell culture supernatant containing HiBIT-RBDwas incubated at the indicated temperature for 7 min and
cleared by centrifugation, and the soluble RBD was measured by addition of HiBIT detection reagent. The samples also contained 0.05% DMSO or 230 µM fenofibric
acid and are significantly different where shown (*p < 0.05). The results (mean ± SD, n  4) are expressed as a fraction of the soluble RBD measured in the absence of
drug.D. ELISA tomeasure inhibition of RBD binding to ACE2 by fibrates. Biotinylated ACE2was captured onto a high bindingmicroplate coated with streptavidin prior to
the addition of RBD preincubated with or without 230 µM bezafibrate, ciprofibrate, fenofibrate, fenofibric acid, gemfibrozil, or acetate control. Data (mean ± SD, n  3)
represented % no inhibitor control and are significantly different from this where shown (*p < 0.05; **p < 0.01; ***p < 0.005). E. A whole cell-binding assay to measure
inhibition of RBD binding to ACE2. COS cells were transfected with ACE2 and incubated on ice with HiBIT-tagged SARS-CoV-2 RBD and the indicated fibrate (230 µM).
After washing, the bound RBD was measured by the addition of LgBIT and NanoLuc substrate. Nonspecific binding was measured in cells not expressing ACE2 and
subtracted from the total binding to determine specific binding. The results mean ± SD, n  4) were normalized to the binding measured in cells exposed to DMSO and
are significantly different where shown (*p < 0.005). F. HiBIT-RBD or COS cells expressing ACE2 were preincubated (37°C) with fenofibric acid (230 µM) before mixing
and measuring binding after a further 20 min. Nonspecific binding was measured as described above. The results (mean ± SD, n  5) are significantly different (*p < 0.05;
**p < 0.01) from the specific binding measured in cells in which HBIT-RBD and fenofibrate were added simultaneously to the cells.
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FIGURE 3 | Fenofibrate and to a lesser extent fenofibric acid reduce SARS-CoV-2 infection at both 24 and 48 h. Vero cells were plated into 96-well plates (8 × 103
cells/well) for 24 h before infecting with 167IU of hCOV-19/England/2/2020 virus isolate in the absence or presence of 230 μM fenofibrate or fenofibric acid. Infection
rates were assessed at 24 and 48 h by staining Vero cells for viral spike protein and counterstaining nuclei with Hoechst. Cells were imaged and analyzed using a Thermo
Scientific CellInsight CX5 HCS platform. Representative images andmean data are shown for Vero cells incubated for 24 h (A andB) and 48 h (C andD). The black
bars are % infected cells and the hatched gray bars are the average number of nuclei scores per field of view (mean ± SD, n  2-3; one-way ANOVA, *p < 0.05 compared
to virus control). E. Supernatant was collected from wells after 48 h of incubation. Virus was heat-inactivated and viral N gene RNA levels were measured directly in the
supernatant using a commercial one-step RT-qPCR reaction. N RNA levels were calculated relative to supernatant from virus control (n  4 experiments).
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cells in the wells. Thus, analysis at 48 h can also identify potential
actions of drugs on viral replication, release, and infection. By 48 h,
59% of Vero cells stained positive for spike protein in virus control
wells with minimal loss of cell numbers (Supplementary Figure S6).
Consistent with the binding assays and of the fibrates studied (all
screened at 230 µM), only fenofibrate reduced virus infection by
∼65–18% compared to virus control (Supplementary Figure S6).
This was not attributable to loss of Vero cell viability as no decrease in
cell number by fenofibrate was seen as measured by the number of
nuclei and by Cell Titer Blue assay (Supplementary Figure S8). No
difference was observed when cells were pretreated or cotreated with
drug and virus (data not shown). Parallel experiments were
performed with a panel of statins (simvastatin, pitavastatin,
rosuvastatin, and pravastatin, (Supplementary Figure S1), drugs
which have largely replaced fibrates as front-line therapy for treating
lipid disorders. When screened at 100 nM, neither pravastatin nor
rosuvastatin reduced infection and had no effect on Vero cell viability
as measured by the number of nuclei (Supplementary Figures
S6–8). At this concentration both simvastatin and pitavastatin
were apparently cytotoxic. Titration experiments (Supplementary
Figure S8) indicated that, at 10 nM, simvastatin and pitavastatin
did not affect cell number but when tested at this concentration,
like the hydrophilic statins, these lipophilic statins also did not
reduce viral infection (Supplementary Figures S6,7). Subsequent
experiments assessed the effect of fenofibrate and fenofibric acid
on infection by SARS-CoV-2. Within 24 h, fenofibrate had
significantly reduced infection levels by ∼60% indicating that
fenofibrate is able to inhibit primary infection (Figure 3A,B).
A reduction was also observed with fenofibric acid, albeit less than
fenofibrate; however, the results were more variable in the
experiments performed and did not reach significance (Figures
3A,B). This pattern was recapitulated at 48 h (Figures 3C,D)
indicating that suppression of infection by fenofibrate is sustained.
These data indicate that, in this setting, fenofibrate and, to a lesser
extent, fenofibric acid are able to reduce primary infection and also
secondary infection rates.
To determine virus levels in cell culture supernatant, virus RNA
levels were measured by multiplex qRT-PCR for viral ORF1ab and N
FIGURE 4 | Fenofibrate reduces SARS-CoV-2 infection level in vitro in a dose-dependent manner. Vero cells were plated into 96-well plates (8 × 103 cells/well) for
24 h before infecting with 167 IU of hCOV-19/England/2/2020 virus isolate in the absence or presence of 1x (230 μM), 0.5x, or 0.25x fenofibrate. Infection was assessed
at 24 h by staining Vero cells for viral spike protein and counterstaining nuclei with Hoechst. Cells were imaged and analyzed using a Thermo Scientific CellInsight CX5
HCS platform. A. Mean infection rates observed at 24 h (n  2–3). B. Supernatant was collected from wells after 48 h of incubation. Virus was heat-inactivated and
viral N gene RNA levels were measured directly in the supernatant using a commercial one-step RT-qPCR reaction. N RNA levels were calculated relative to supernatant
from virus control (n  4). To determine the role of PPARα, 48 h infection experiments were performed in the absence or presence of the PPAR-alpha antagonist GW6471
(1 μM). Mean data from two to three experiments are shown in (C andD).C shows% infected cells andD the average number of nuclei scores per field of view. Statistical
significance was calculated by one-way ANOVA. *p < 0.05 compared to virus control.
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genes on heat-inactivated culture supernatant from 48 h experiments.
While ORF1ab RNA levels were detectable in virus control
supernatant, no signal was detected in supernatant from drug-
treated cells implying a reduction in virus RNA (data not shown).
However, a signal for the viral N gene was detectable by qRT-RCR in
all samples. Consistent with the reductions seen in infection levels,
fenofibrate significantly reduced viral N gene RNA levels, whereas the
results with fenofibric acid were more variable (Figure 3E).
Furthermore, the effect of fenofibrate on infection rates and viral
RNA levels in culture supernatant was dose-dependent as determined
by doubling dilution experiments (1x: 230 μM; Figures 4A,B).
Fenofibrate works as an antihyperlipidaemia agent by acting as a
PPARα agonist. Treatment with the PPARαantagonist GW6471 did
not appreciably alter the antiviral actions of fenofibrate (Figures
4C,D) in this setting.
Fenofibrate Inhibits Infection of Vero Cells
by the Italy/UniSR1/2020 Virus Isolate
To confirm the infection results observed with hCOV-19/England/2/
2020 isolate in experiments performed at the University of
Birmingham, the effect of fenofibrate and fenofibric acid was
assessed on plaque formation in Vero cells infected with the Italy/
UniSR1/2020 SARS-CoV-2 isolate independently at San Raffaele
Scientific Institute in Milan. Both the hCOV-19/England/2/2020
isolate and Italy/UniSR1/2020 isolate are identical to the original
Wuhan viral strain. Vero cells were pretreated for 1 hwith fenofibrate
or fenofibric acid (“pretreatment”). Alternatively, the cells were
exposed to the drug and the virus at the same time (cotreatment).
After 1 h, the virus was removed and plaques were allowed to form.
Fenofibric acid inhibited plaque formation at concentrations
clinically achievable in patients (pretreatment IC50 14 μM;
cotreatment IC50 7 μM) (Figure 5). Fenofibrate also reduced the
number of plaques formed, but notably less potently. As observed for
the hCOV-19/England/2/2020 strain, there was no substantial
difference between the pretreatment and cotreatment experiments.
Thus, using two different virus isolates, we demonstrate that
fenofibrate or its active metabolite fenofibric acid are able to
significantly reduce SARS-CoV-2 infection in cell culture
models.
DISCUSSION
The development of new more infectious SARS-CoV-2 variants
has resulted in a rapid expansion in infection rates and deaths in
FIGURE 5 | Fibrate inhibition of SARS-COV-2 infection of Vero cells. Antiviral effect of fibrates added 1 h before infection or in cotreatment with infection in Vero cells
with 50 PFU of SARS-CoV-2. ND, not determined due to solubility issues. The results are expressed as the number of PFU/well (mean ± SD, n  3). The number of
plaques was significantly different (2-way ANOVA) in cells treated with fenofibric compared to fenofibrate where shown DMSO (*p < 0.001). Compared to cells treated
with drug solvent, the number of plaques was significantly different in cells treated with fenofibric acid (p < 0.001, all concentrations tested) and in cells treated with
fenofibrate (p < 0.01, 10 µM fenofibrate; p < 0.001, 50 µM fenofibrate).
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several countries around the world, especially the
United Kingdom, US, and Europe. While vaccine programs
will hopefully reduce infection rates and virus spread in the
longer term, there is still an urgent need to expand our
arsenal of drugs to treat SARS-CoV-2-positive patients. Using
an unsupervised approach, we have identified that the off-patent
licensed drug fenofibrate has the potential to treat SARS-CoV-2
infections. The drug was identified through a screen of approved
drugs to identify those which alter the dimerization of ACE2.
Clofibrate was identified as a hit in this screen and testing of other
fibrates led to the identification of fenofibrate as being the most
likely to be effective as an antiviral agent. Fenofibric acid also
appears to affect the stability of spike protein RBD and inhibit
binding to ACE2. Importantly, these effects on RBD by fenofibric
acid/fenofibrate correlated with decreases in SARS-CoV-2
infection rates in vitro using two different virus assays
(staining for spike protein and plaque formation) in two
independent laboratories.
The ACE2 dimerization assays depend on the colocalization
of LgBIT and SmBIT brought about by the formation of ACE2
dimers. No signal was observed using protein kinase A
subunits that do not interact with ACE2 and overexpression
of unlabeled ACE2 suppressed the signal from the NanoBIT
reporters, giving confidence that the assay measures the
interaction of ACE2 protomers. Although described here as
a dimerization assay, the assay may not discriminate between
dimer formation and higher-order oligomers, and drugs
showing activity in the dimerization assay could
alternatively elicit conformational changes in ACE2
complexes which improve the interaction of the NanoBIT
reporters. We also acknowledge that although ACE2 is well-
established as a membrane protein and this is supported by our
own binding assays, we have not formally shown that the
NanoBIT-tagged proteins are located on the cell membrane.
All the fibrates tested showed some activity in the dimerization
assays, but the most pronounced effects were observed with
fenofibric acid. Following oral administration of fenofibrate,
the ester prodrug is completely converted to the free acid
(Figure 6) in a reaction thought to be catalyzed by
carboxylesterases. The prodrug fenofibrate (the isopropyl
ester of fenofibric acid) was inactive in the dimerization
assay, suggesting that the free carboxylic acid is necessary.
In addition to effects on ACE2, DSF showed that all the
fibrates destabilized the viral spike protein RBD and lowered
its “melting” temperature. The most potent effects were again
seen with fenofibric acid. These results were corroborated with
a modified “CETSA” assay which measured RBD aggregation
after thermal denaturation. The effects of fenofibric acid on
RBD may contribute to its inhibition of the binding of RBD to
ACE2 in ELISA and cell-binding studies performed at 37°C.
When measured in cells at 0°C, the fibrates did not inhibit
binding to ACE2; this temperature is likely to prevent melting,
providing a potential explanation for the lack of activity of
fibrates in binding assays at lower temperatures. To provide
FIGURE 6 | Potential mechanisms by which fenofibrate may improve the treatment of SARS-COV-2 infections. Fenofibric acid, the metabolite of fenofibrate,
stimulates ACE2 dimerization, destabilizes the RBD, and exerts metabolic effects which are likely to reduce infection. Fenofibric acid possesses anti-inflammatory
properties which are likely to blunt the immune response and correspondingly alleviate symptoms. Lastly, fenofibric acid inhibits platelet activation and aggregation,
which is anticipated to reduce the hemodynamic problems seen in SARS-COV2 patients.
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evidence for a dual mechanism of action of fenofibrate on both
RBD and ACE2, we compared preincubation of cells or RBD
with fenofibric acid to experiments when binding of RBD was
measured when all three reagents were coincubated.
Preincubation of fenofibrate with either ACE2-expressing
cells or RBD increased the inhibition of RBD binding by
fenofibric acid, consistent with the drug having effects on
both RBD and ACE2. Taken together, these data prompted
us to evaluate whether fenofibric acid or fenofibrate would
reduce infection by SARS-CoV-2.
To provide robust data evaluating the potential of fenofibric
acid/fenofibrate to inhibit infection by SARS-CoV-2, the drugs
were evaluated independently in two separate laboratories
using different viral infection assays performed on Vero
cells and two separate SARS-CoV-2 isolates, both of which
are identical to the original Wuhan strain (hCOV-19/England/
2/2020 and Italy/UniSR1/2020). In both cases, fenofibrate/
fenofibric acid was found to significantly reduce infection
rates. Fenofibrate/fenofibric acid decreased the number of
Vero cells staining positive for viral spike protein at 24 h
indicating inhibition of primary infection. The number of
cells infected 48 h after infection was also significantly
reduced, demonstrating the potential for sustained
inhibition of infection. This was further confirmed by PCR
which showed a reduction in viral mRNA released by the cells
into the culture supernatant. Likewise, we saw significant
reductions with fenofibric acid/fenofibrate in plaque
formation assays which are considered the gold-standard
assay for measuring infectivity by SARS-CoV-2. Several
assays demonstrate that the reduced viral infection was not
due to a cytotoxic effect of the fibrates in the host cells.
Considering that fenofibrate is used in the treatment of
hypercholesterolaemia and hyperlipidaemia, the effect of
several statins on SARS-CoV-2 infection was also assessed.
These included both hydrophilic (pravastatin; rosuvastatin)
and lipophilic statins (pitavastatin; simvastatin). None of the
statins inhibited viral infection, suggesting that the antiviral
effect was not mediated by inhibition of cholesterol synthesis.
The differences we observed in potency between fenofibrate
and fenofibric acid in the two antiviral assays may reflect
different strains of the virus or different methodologies.
Although we cannot presently fully explain these, it is clear
that fenofibrate or its metabolite fenofibric acid demonstrated
anti-SARS-CoV-2 activity.
Fenofibric acid was identified as a potential antiviral agent
through its effects on ACE2 dimerization, but it remains to be
clarified to what extent the effects of fenofibrate/fenofibric
acid on dimerization contribute to its antiviral activity. The
mechanism by which increased dimerization could inhibit
viral infection was not investigated and several explanations
are plausible. It was not possible to measure the effect of
fibrates on dimerization of ACE2 in streptavidin
precipitation assays. This may reflect the insensitivity of
this latter method or that fenofibrate alters the
conformation of ACE2 rather than inducing dimerization.
Structural studies have shown that ACE2 adopts “open” and
“closed” conformations (Yan et al., 2020) which may be
detected by the NanoBIT reporters. The open and closed
conformations may also affect RBD binding to each ACE2
protomer or the number of spike proteins that can bind to an
ACE2 dimer, thereby affecting the avidity of the virus for
cells. Conformational changes in ACE2 may also affect its
susceptibility to proteolysis by TMPRSS2. The suggestion
that the antiviral activity of fenofibrate depends at least in
part on effects on ACE2 also offers advantages over drugs that
inhibit viral proteins. Mutations in the viral genome are less
likely to affect the antiviral activity of drugs which target
human rather than viral proteins. Excitingly, fenofibrate also
destabilized the RBD and reduced its binding to ACE2. It is
highly likely that this contributes to the reduced infection in
cells treated with fenofibrate. This also suggests that
fenofibrate has multiple mechanisms of action, making it
less likely that resistance to it will quickly emerge and
fenofibrate may retain activity against newly emerging
strains of SARS-CoV-2. However, our data suggest that the
antiviral activity of fenofibrate measured in the infection
assays presented here is not mediated by the transcription
factor PPARα. The efficacy of fibrates in the treatment of
hyperlipidaemia depends on their ability to activate PPARα
However, GW6471, a PPARα antagonist (Xu et al., 2002), did
not prevent fenofibrate from inhibiting viral infection.
To our knowledge, this is the first experimental evidence
that fenofibrate can modulate RBD and ACE2 proteins and
inhibit SARS-CoV-2 infection. Importantly, others have also
proposed its therapeutic use in SARS-CoV-2. These
proposals are based on pharmacological effects of
fenofibrate that are additional to the ones we have
identified here (summarized in Figure 6). Fenofibrate
increases the levels of the glycosphingolipid sulfatide and
this has been proposed to reduce SARS-CoV-2 infection
(Buschard, 2020). SARS-CoV-2 infection is associated with
overproduction of cytokines, such as TNF-α, IFN-γ, IL-1, IL-
2, and IL-6, and subsequently a cytokine storm that induces
several extrapulmonary complications including myocardial
injury, myocarditis, acute kidney injury, impaired ion
transport, acute liver injury, and gastrointestinal
manifestations such as diarrhea and vomiting (Gupta
et al., 2020; Lee and Choi, 2021). Similar to
dexamethasone, fenofibrate has been shown to suppress
airway inflammation and cytokine release including TNF-
α, IL-1, and IFN-γ in both mouse and human studies (Madej
et al., 1998; Delayre-Orthez et al., 2008; Stolarz et al., 2015).
Fenofibrate has also been shown to have antithrombotic and
antiplatelet activities (Jeanpierre et al., 2009; Lee et al., 2009)
reduce fibrinogen levels and increase clot permeability,
thereby enhancing fibrinolysis (Undas et al., 2006). These
properties may reduce or prevent hypercoagulability seen in
the late stage of disease in many SARS-CoV-2 patients
(Rogosnitzky et al., 2020). A meta-analysis has also
suggested that fenofibrate may be useful in the treatment
of hepatitis C infection (Grammatikos et al., 2014). Lastly, we
note a preprint from the group of Nahmias that has also
suggested that fenofibrate may have clinical effects against
SARS-CoV-2 infection which depends on the PPARα
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mediated alterations in host cell metabolism (Ehrlich et al.,
2020). Based on the data in this preprint, two clinical trials
have been registered using fenofibrate in SARS-CoV-2
patients requiring hospitalization (Hospital of the
University of Pennsylvania (NCT04517396) and Hebrew
University of Jerusalem (NCT04661930)). The metabolic
effects of fenofibrate may be mediated not only by its
cognate target, PPARα, but also by activation of AMPK
(Murakami et al., 2006) which regulates protein synthesis
and autophagy pathways through mTORC1.
Given the current acceleration in infection and death rates
observed in several countries, we strongly advocate clinical
trials of fenofibrate in patients with SARS-CoV-2 requiring
hospitalization. Fenofibrate has a relatively safe history of
use, the most common adverse effects being abdominal pain,
diarrhea, flatulence, nausea, and vomiting. The half-life of
fenofibric acid is 20 h (Desager et al., 1996), allowing
convenient once daily dosing. The recommended doses in
the United Kingdom (up to 267 mg) provide plasma
concentrations (Cmax 70 μM; Css 50 µM) comparable to
those at which we and others have seen antiviral activity,
Finally, if proven effective, fenofibrate is available as a
“generic” drug and consequently is relatively cheap,
making it accessible for use in all clinical settings,
especially those in low and middle-income countries.
Preliminary data indicate that fenofibrate is equally
effective against the B.1.1.7 variant (data not shown)
implying that mutations in S protein are unlikely to affect
the efficacy of fenofibrate. There are a number of medical
conditions which contraindicate the use of fenofibrate, such
as significantly impaired kidney function, and these could
potentially limit its use in the treatment of COVID patients.
There are also a number of drug interactions with fenofibrate
which are potentially severe, although some of these may be
avoided by temporarily withholding the interacting drug.
Appropriate risk-benefit analysis will be necessary once the
clinical antiviral activity of fenofibrate is defined to identify
which SRS-COV2 patients can safely be treated with
fenofibrate. While further studies to clarify the precise
mechanism of the antiviral activity of fenofibrate are
ongoing, our data support the clinical evaluation of
fenofibrate in the community infection setting and also in
patients requiring hospitalization. One possibility is that
fenofibrate is tested in newly diagnosed symptomatic patients,
who do not require hospitalization, in whom reduction in viral
infection levels by fenofibrate would reduce disease severity and the
spread of infection to other individuals.
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